Sanjiu Medical Kicks Off Industrial Park Operation
This article was originally published in PharmAsia News
With the backing of main shareholder China Resources Enterprise, restructured Sanjiu Medical & Pharmaceutical has finished constructing its industrial park and begun operations. The 300-million-yuan phase one project, located in the city's Guanlan High Tech Area, occupies 110,000 square meters. Sanjiu will acquire another 70,000 square meters for phase two, earmarked for related pharmaceutical production and auxiliary facilities. According to CR Enterprise, Sanjiu will focus on OTC brands as its core business, with TCM prescription and free-decocting TCM as fast-growth areas. The firm will reorganize its antibiotics and generics business to enter the tier-three end-user market. The latest event marks a key milestone for CR Enterprise, which will base its pharmaceutical headquarters in Shenzhen to further boost the business. (Click here for more - Chinese Language)
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.